Table 1.
Summary of clinical and biological features for patients in the study.
Table 2.
Prognostic significance of FCM MRD at different cutoffs.
Figure 1.
Prognostic significance of MRD as detected by FCM at day 15 and day 33.
Event-free survival (left) and incidence of relapse (right) of patients stratified according to FCM MRD Model I (upper panel) and Model II (lower panel).
Figure 2.
Prognostic significance of FCM MRD for patients with selected features.
Incidence of relapse for patients with (A) B-lineage ALL (B) in ALL IC-BFM 2002 standard risk (left) or intermediate risk (right). Upper panels were stratified by Model I and lower panels were by Model II.
Figure 3.
Prognostic significance of MRD as detected by PB plasma DNA PCR at day 15.
(A) Correlation of PB plasma DNA MRD with FCM MRD at day 15. Spearman r test was used for statistical analysis. (B–C) Comparison of PB plasma DNA MRD level (cutoff: 10−4) at day 15 with (B) event-free survival and (C) occurrence of relapse. (D–F) Incidence of relapse for patients stratified according to PB plasma MRD cutoff at 10−4 with (D) B-lineage ALL, in ALL IC-BFM 2002 standard risk (E) or intermediate risk (F).
Table 3.
Prognostic significance of PB plasma DNA MRD at different cutoffs.
Table 4.
Multivariate Cox regression analysis for FCM and plasma DNA MRD.